OnKure, Inc. Raises $55 Million Series B Financing
03/04/21, 3:44 PM
Location
boulderMoney raised
$55 million
Round Type
series b
OnKure, Inc., a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, today announced that it has raised $55 million in a Series B financing. Proceeds will be used to advance the Company’s next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
Company Info
Company
On Kure
Location
boulder, colorado, united states
Additional Info
OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure’s drug candidates aim to treat patients through restoration of the epigenetic landscape, delaying resistance to other targeted therapies and exploiting synthetic lethalities. OnKure’s most advanced candidate, OKI-179, a potent and selective Class I HDAC inhibitor, is moving into Phase 2 studies in targeted populations. For more information about OnKure, please visit www.onkuretherapeutics.com.